Meeting
2023 ASCO Annual Meeting
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
Authors
Luis G. Paz-Ares
Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain
Luis G. Paz-Ares , Enriqueta Felip , Myung-Ju Ahn , Fiona Helen Blackhall , Hossein Borghaei , Byoung Chul Cho , Melissa Lynne Johnson , Suresh S. Ramalingam , Martin Reck , Alicia Zhang , Chia-Hsin Ju , Mukul Minocha , Sujoy Mukherjee , Gaurav Suri , Danielle Jandial , D Gwyn Bebb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05740566
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8611)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8611
Abstract #
TPS8611
Poster Bd #
232a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.
First Author: Alejandro Navarro
Poster
2016 ASCO Annual Meeting
CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).
First Author: Leora Horn
Poster
2022 ASCO Annual Meeting
Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
First Author: Suresh S. Ramalingam
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
First Author: Taofeek Kunle Owonikoko